Intravesical Gemcitabine

This study is for people with superficial bladder cancer (cancer that has not yet grown deep into the bladder wall). It tests whether a drug called gemcitabine, delivered directly into the bladder through a catheter (a tube) once a week, can prevent the cancer from coming back after it has been surgically removed. The study is open to people with newly diagnosed bladder cancer as well as those whose cancer has come back after previous treatment with BCG or mitomycin. You may be eligible if: - You are 18 years of age or older - You have superficial transitional cell carcinoma of the bladder confirmed by tissue or cell sample - You have either newly diagnosed bladder cancer not previously treated with bladder washes, OR cancer that has come back after at least one course of BCG or Mitomycin (with at least 12 weeks since the last treatment) - Your general health and blood counts are within required levels You may NOT be eligible if: - You have previously had radiation treatment to the bladder - Your cancer has grown into the muscle of the bladder - You have a current urinary tract infection - You have other concerns that make bladder treatment unsafe at this time Talk to your doctor about whether this trial might be right for you.